ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

filgotinib

Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.

Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.

Drug pageGLPG0634: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 22, 201646 company-led studies, 4 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lakefront Biotherapeutics NVits history only230 open or runningphase 3since Sep 22, 2016Aug 10, 2010none ahead
Gilead Sciences160 open or runningphase 3since Aug 17, 2016Aug 17, 2016none ahead
Alfasigmaits history only74 open or runningphase 3since Sep 22, 2016Sep 22, 2016Jun 2027phase 3 · NCT07554495

Also a collaborator on its studies: Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2016First studies: 3 phase 3 studies in Arthritis, RheumatoidFirst studyNCT02873936, NCT02886728, NCT02889796
  2. Sep 22, 2016Phase 3 study in Colitis, UlcerativeNCT02914522 · 1,351 enrolled · United States, Argentina, Australia and more
  3. Feb 6, 2017Phase 2 study in Small Bowel Crohn's DiseaseNCT03046056 · 78 enrolled · United States, Austria, Belgium and more
  4. Mar 8, 20172 phase 2 studiesNCT03077412, NCT03100942
  5. Apr 25, 2017Phase 2 study in Lupus Erythematosus, CutaneousNCT03134222 · 47 enrolled · United States, Canada
  6. Jun 30, 2017Phase 2 study in Noninfectious UveitisNCT03207815 · 74 enrolled · United States, Australia, Canada and more
  7. Sep 14, 2017Phase 2 study in Lupus Membranous NephropathyNCT03285711 · 9 enrolled · United States
  8. Jan 25, 2018Phase 1 study in Arthritis, RheumatoidNCT03417778 · 20 enrolled · United States, Germany, New Zealand
  9. Oct 2, 20192 phase 3 studies in Arthritis, PsoriaticNCT04115839, NCT04115748
  10. Jul 20, 20202 phase 3 studies in Spondylitis, AnkylosingNCT04483700, NCT04483687
  11. Oct 23, 2020Phase 1 study in Arthritis, RheumatoidNCT04608344 · 27 enrolled · United States

TargetBeta

“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
delgocitinibruleLEO Pharmaphase 321

Studies

All 16 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04608344Arthritis, Rheumatoid · United States1CompletedJan 13, 202127
NCT04483700Spondylitis, Ankylosing3WithdrawnOct 20220
NCT04483687Spondylitis, Ankylosing3WithdrawnJan 20230
NCT04115839Arthritis, Psoriatic · United States, Australia, Belgium and more3TerminatedJan 4, 2021106
NCT04115748Arthritis, Psoriatic · United States, Australia, Bulgaria and more3TerminatedJan 19, 202167
NCT03417778Arthritis, Rheumatoid · United States, Germany, New Zealand1CompletedAug 9, 201820
NCT03285711Lupus Membranous Nephropathy · United States2CompletedMay 3, 20199
NCT03207815Noninfectious Uveitis · United States, Australia, Canada and more2TerminatedDec 29, 202074
NCT03134222Lupus Erythematosus, Cutaneous · United States, Canada2CompletedMar 13, 201947
NCT03100942Sjogren's Syndrome · United States, Poland, Spain and more2CompletedJan 10, 2019152
NCT03077412Fistulizing Crohn's Disease · United States, Austria, Belgium and more2CompletedJan 20, 202157
NCT03046056Small Bowel Crohn's Disease · United States, Austria, Belgium and more2CompletedJul 20, 202078
NCT02914522Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedMar 31, 20201,351
NCT02889796Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedJul 4, 20181,759
NCT02886728Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedOct 5, 20181,252
NCT02873936Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedMar 20, 2018449

How it is read

Names in the registry

  • “Filgotinib”, 32 entries
  • “GLPG0634”, 11 entries
  • “filgotinib”, 3 entries
  • “GLPG0634 50 mg”, 1 entry
  • “GLPG0634 100 mg”, 1 entry

Codes read as this program: GLPG0634.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.